CS
Castle Biosciences, Inc.
CSTL · NASDAQ
$34.99 -1.77% (-$0.63)
1M +4.54%
Market Cap $1.07B
P/E Ratio -
Div. Yield -
ROE 4.15%
Bulios Fair Price
$39.7
13.5% upside
Current Price
$34.99
Undervalued Fair Value Overvalued
According to Bulios Fair Price, CSTL is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
3/9Valuation
70 /100
Cheap P/S 2.99x
P/B 2.27x
P/E N/A
Growth
90 /100
Growing Rev. growth 35.94%
Book val. growth 5.66%
EPS growth N/A
Profitability
22 /100
Weak Gross margin 77.26%
FCF margin 0.14%
Net margin 5.43%
Quality
8 /100
Poor ROIC 6.38%
Asset turnover 0.64x
ROE 4.15%
Debt
69 /100
Low Debt/Equity 0.08x
Int. coverage -50.21x
Current ratio 6.04x
Stability
31 /100
Unstable Beta 1.00x
Profitable years 0
Rev. volatility 30.42%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about CSTL
Online
Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Derek J. Maetzold
Employees
1,002
Headquarters
Friendswood
Upcoming events
02 NOV
Earnings
Upcoming earnings report